Compare MMLP & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMLP | OVID |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.3M | 117.5M |
| IPO Year | 2002 | 2017 |
| Metric | MMLP | OVID |
|---|---|---|
| Price | $2.88 | $1.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 21.2K | ★ 1.6M |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $713,263,000.00 | $6,610,000.00 |
| Revenue This Year | $4.19 | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 945.89 |
| 52 Week Low | $2.21 | $0.24 |
| 52 Week High | $3.90 | $2.01 |
| Indicator | MMLP | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 56.32 | 46.78 |
| Support Level | $2.75 | $1.57 |
| Resistance Level | $3.02 | $1.65 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 70.31 | 5.00 |
Martin Midstream Partners LP has a diverse set of operations focused in the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and natural gas liquids marketing, distribution and transportation services. Company operates in four segment Terminalling and storage, Transportation, Sulfur service and Specialty products segment. Majority of the revenue derived from Specialty products segment.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.